CyFlow CD266 PE (RUO)
| 品番 | AD595460 | ||
|---|---|---|---|
| 抗体名 | Anti-H/M CD266 PE,ITEM-4 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 0.1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG2b PE (CP922237) |
||
| 反応性|交差吸着 | Human | Mouse | レーザー | Blue, Green, Yellow |
| 抗原 | CD266, TWEAK-R, TNFRSF12A | 最大蛍光波長 | 576 nm |
| クローン | ITEM-4 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgG2b | 研究分野 | Immunophenotyping | Apoptosis |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-H/M CD266 PE,ITEM-4
特異性
The mouse monoclonal antibody ITEM-4 recognizes CD266 (TWEAK R) antigen, a TNFR superfamily receptor for CD255 (TWEAK), a TNF-like weak inducer of apoptosis.
抗原情報
CD266 (TWEAK R, TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14), is a receptor for CD255 (TWEAK), the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.
利用方法
The reagent is designed for Flow Cytometry analysis. Working concentrations should be determined by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J·Immunol. 2003·Jan·1; 170(1):341‑8. <·PMID:·12496418·>
• Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF‑like weak inducer of apoptosis differentially activate the classical and noncanonical NF‑kappa B pathway. J·Immunol. 2010·Aug·1; 185(3):1593‑605. <·PMID:·20610643·>
• Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak‑induced apoptosis in PC‑3 prostate cancer cells. PLoS·One. 2012; 7(10):e47440. <·PMID:·23077618·>
• Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp·Ther·Med. 2011·Jan; 2(1):103‑108. <·PMID:·22977477·>